Solvo Biotechnology
Private Company
Funding information not available
Overview
Solvo Biotechnology, founded in 2000 and acquired by Charles River Laboratories, is a specialized provider of drug transporter and ADME/Tox products and services. The company has established itself as a scientific leader in the transporter field, offering validated assays, kits, and consulting services critical for regulatory submissions related to drug-drug interactions. Its business model is entirely service- and product-based, catering to the pharmaceutical industry's need to de-risk drug development by understanding transporter-mediated disposition and toxicity. Solvo's deep expertise and regulatory alignment position it as a key partner in the non-clinical safety and pharmacokinetics testing market.
Technology Platform
Comprehensive suite of in vitro assay systems for drug transporter and metabolism studies, including membrane preparations, transporter kits, cell-based assays (Caco-2, hepatocytes), and specialized platforms like HepatoPac®. Services are designed for regulatory compliance (FDA/EMA) in drug-drug interaction assessment.
Opportunities
Risk Factors
Competitive Landscape
Solvo competes in the specialized transporter services segment against other niche CROs (e.g., Optivia Biotechnology) and the in-house ADME departments of large pharmaceutical companies. Its primary competitive advantage is deep, focused expertise and a reputation for regulatory compliance. As part of Charles River, it also competes indirectly with other large, full-service CROs like LabCorp's Covance and ICON's PRA, where its specialty offerings can be a differentiator within a broader service package.